arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

ABBOTT LABORATORIES

ABT
$107.81 ▼ -0.13 (-0.13%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
20 Visible periods
34 Metrics
Peer-ranked Benchmarks
Price Chart
75
Health
Good
Bullish
auto_awesome

Analytical Summary

ABBOTT LABORATORIES shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $187.7B
Dividend Yield 2.23%
Revenue Growth 5.7%
Op. Margin 18.2%
ROIC 9.5%
FCF / Share $4.25
Trailing P/E 28.9x
Price / Book 3.6x
FCF Yield 3.9%
Debt / Equity 0.25
info Valuation on last close. End-of-day price, Aug 7, 2026.

20-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$44.33B
↑ +5.7%
Net Income Profit after all expenses
$6.52B
↓ -51.3%
Operating Margin Operating profit as % of sales
18.2%
↑ +11.7% 72th
FCF / Share Free cash flow per share
$4.25
↑ +16.4%
Long-Term Debt Long-term obligations
$12.93B
↓ -8.5%
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
74
Returns
75
Financial Health
77
Cash Quality
70

Dividend History

Dividend / share · sourced from SEC filings
$2.40 Latest / share
+7.1% YoY
+7.4% 3-yr CAGR

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 20 years · 74 quarters